Fracture Risk and Sodium-Glucose Transport Inhibitors
Nov 19, 2019
Editor: Steve Freed, R.PH., CDE
Author: Usif Darwish, PharmD Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences
Did the FDA make a mistake by labeling SGLT2 inhibitors as a fracture risk?
In recent years, there have been controversial warnings for the use of SGLT-2 Inhibitors that suggest an increased risk of fracture when placed on one SGLT2 inhibitor, canagliflozin. In 2015, the US FDA added a warning on canagliflozin, indicating that patients on canagliflozin must use caution because of a fracture risk associated with the diabetes medication. This conclusion came from previous data....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.